Full Press Release Details
Verify to continue
To continue, please confirm that you're a human (and not a spambot).
Checking if the site connection is secure
vimeo.com needs to review the security of your connection before
proceeding.
KURA Neutral Sentiment
Dr. Erba explains the different combinations KOMET-008 will evaluate and how it differs from KOMET-007
Key Takeaway: The article discusses Dr. Erba's explanation of the various combinations that the KOMET-008 trial will evaluate, highlighting its differences from the previous KOMET-007 trial. However, specific details about the combinations or the trials themselves are not provided in the text.
Price reaction · baseline $12.09 (2023-12-18T16:49:00.000Z) · hit during market hours · 2 other KURA headline(s) in the window, move may be shared
day 0 close · peak
+2.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+116%
120-day peak, hindsight
Typical move
5.7%
average across 9 past catalysts
Cash runway
~25 mo
Low dilution risk
Lead asset
Tipifarnib
Phase 2 · Leukemia, Myelomonocytic, Chronic